Friday, 27 February 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 27 February 2026
News

Sales are booming for these drugs

Posted 27 February 2026 AM

With top-line Federal Government spending on the R/PBS increasing by a tenth over 2025, much of that growth was taken by just a few drugs, with the top ten fastest growers adding $872.7 million to the cost.

The fastest grower of pre-rebate R/PBS reimbursements over the 2025 calendar year was Pfizer's transthyretin stabiliser Vyndamax. The drug earned Pfizer an extra $145.1 million in headline reimbursements, almost quadrupling what it earned in 2024 after listing in May that year.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (11)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (5)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.